INDICATIONS FOR USE

FOXO4-DRI is an experimental peptide used in anti-aging research. Its proposed application is to selectively target senescent cells, thereby improving tissue function and reducing age-related inflammation.

ROUTE OF ADMINISTRATION

• Subcutaneous injection.

COMMON INITIAL DOSING REGIMENS

• Inject 0.3mg-0.5mg (30-50 units via insulin syringe) SQ daily for 7 days, every other week.

MECHANISM OF ACTION

• FOXO4-DRI inhibits the interaction between FOXO4 and p53 in senescent cells. By disrupting this interaction, senescent cells undergo apoptosis, thereby reducing cellular senescence and its associated pro-inflammatory secretory phenotype.

COMMON SIDE EFFECTS

• Due to its experimental status, side effects in humans are largely unknown. Potential risks include:

• Immune: Injection site reactions or systemic immune activation.

• Metabolic: Possible off-target effects leading to fatigue or loss of appetite.

• Rare: Theoretical risks include unintended apoptosis in non-senescent cells, leading to tissue damage.

CONTRAINDICATIONS

• Absolute: Hypersensitivity to the peptide or its components.

• Relative: Use cautiously in patients with active infections, autoimmune diseases, or ongoing malignancies, as effects on the immune system are not fully understood.

DISCLAIMER

• This medication is experimental and not FDA-approved.

LEARN MORE

• Evidence hound? Review our comprehensive listing of PubMed direct links to original research related to this medication.